Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR) Short Interest Down 15.1% in March

Posted by James Quigley on Apr 17th, 2026

Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Get Free Report) saw a large decrease in short interest during the month of March. As of March 31st, there was short interest totaling 528 shares, a decrease of 15.1% from the March 15th total of 622 shares. Based on an average daily volume of 742 shares, the days-to-cover ratio is currently 0.7 days. Currently, 0.3% of the company’s shares are short sold.

Amplify Weight Loss Drug & Treatment ETF Price Performance

NYSEARCA THNR traded up $0.27 during mid-day trading on Friday, reaching $25.14. 592 shares of the stock were exchanged, compared to its average volume of 2,307. The stock has a market cap of $4.27 million, a P/E ratio of 24.31 and a beta of 0.58. Amplify Weight Loss Drug & Treatment ETF has a one year low of $19.97 and a one year high of $27.28. The stock has a 50 day simple moving average of $25.09 and a 200-day simple moving average of $25.03.

Institutional Investors Weigh In On Amplify Weight Loss Drug & Treatment ETF

An institutional investor recently raised its position in Amplify Weight Loss Drug & Treatment ETF stock. Jane Street Group LLC boosted its holdings in Amplify Weight Loss Drug & Treatment ETF (NYSEARCA:THNR – Free Report) by 5.1% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 24,891 shares of the company’s stock after purchasing an additional 1,215 shares during the quarter. Jane Street Group LLC owned about 19.15% of Amplify Weight Loss Drug & Treatment ETF worth $536,000 at the end of the most recent quarter.

Amplify Weight Loss Drug & Treatment ETF Company Profile

(Get Free Report)

The Amplify Weight Loss Drug & Treatment ETF (THNR) is an exchange-traded fund that is based on the VettaFi Weight Loss Drug index. The fund tracks a modified market cap-weighted index of companies from developed markets that manufacture and enable GLP-1 agonist pharmaceutical businesses. THNR was launched on May 21, 2024 and is issued by Amplify Investments.